drugset / Trial / NCT05304130

A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab

NCT05304130

Phase 1 Withdrawn GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) profiles of otilimab in healthy Japanese participants.

Timeline

Start
2023-02-08
Primary completion
2023-05-04
Completion
2023-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Otilimab Monoclonal antibody

Indications